New antibiotic could fight tough diabetic foot infections
NCT ID NCT05369052
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests a new antibiotic called contezolid against a standard one (linezolid) for moderate to severe diabetic foot infections. About 865 adults with diabetes and a foot infection will receive either drug for 2 to 4 weeks. The goal is to see if the new drug works as well or better and has fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
contezolid acefosamil (IV) and contezolid (oral)
What this could lead to
If successful, this could provide a new antibiotic option for treating serious diabetic foot infections, potentially with fewer side effects than current treatments.
What could go wrong
This is an early Phase 3 trial, so results are not yet proven. The new drug may not be more effective or safer than the existing antibiotic linezolid.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC FOOT INFECTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Daugavpils Regional Hospital
RECRUITINGDaugavpils, Latvia
-
GMV Care& Research - Maria Cecilia Hospital
RECRUITINGCotignola, Italy
-
ILD Research Center
RECRUITINGVista, California, 92081, United States
-
Instytut Medycyny Wsi im. W. Chodzki
RECRUITINGLublin, Poland
-
JSC Vian - West Georgia Medical Center
RECRUITINGKutaisi, Georgia
-
LTD High Technology Hospital Med Center
RECRUITINGBatumi, Georgia
-
MHAT Sveti Nikolay Chudotvorets EOOD
RECRUITINGLom, Bulgaria
-
Medical Institute Ministry of Interior Central Clinical Base
RECRUITINGSofia, Bulgaria
-
Multiprofile Hospital for Active Treatment - KANEV
RECRUITINGRousse, Bulgaria
-
New Hope Research Development
RECRUITINGCorona, California, 92882, United States
-
PODEMA Sp. z o.o.
RECRUITINGWarsaw, Poland
-
South-Estonian Hospital Ltd.
RECRUITINGVõru, Estonia
-
University Clinical Center Kragujevac
RECRUITINGKragujevac, Serbia
-
University Multidisciplinary Hospital for Active Treatment and Emergency Medicine 'N. I. Priogov´
RECRUITINGSofia, Bulgaria